GLPwatch
Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients
NCT03986008 · Unknown status
Last updated 2026-05-28This clinical trial tests whether the medication benaglutide affects weight and gut bacteria in adults with obesity over a 3-month period.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 60 people Planned (estimated).
Who can join Ages 18–65 · all sexes
Timeline Started 2019-12 · est. completion 2021-12
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT03986008 ↗
Description as written by the study sponsor.
The purpose of this studay is to evaluate the effects of Benaglutide on the treatment of subjects with obesity.
Treatments tested
- Benaglutide also known as rhGLP-1(7-36) Drug
The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
- Liraglutide also known as Victoza Drug
The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
| Main thing measured | Weight Change at 3 months |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Conditions studied | Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03986008 ↗